Humacyte, Inc. (HUMA) Financial Statements
Humacyte, Inc. (HUMA) reported trailing twelve-month revenue of $2.1M (up 159.3% year on year) and net income of -$96.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$97.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HUMAHumacyte, Inc.Follow HUMA — free
—
Price chart with a free account
- Market cap
- 121.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Nov, in 13 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|
| Revenue | 2.0 | 2.1 | |
| Gross profit | -7.7 | — | |
| Research & development | 69.3 | 69.5 | |
| Operating income | -108.1 | -111.2 | |
| Pre-tax income | -40.8 | -96.7 | |
| Income tax | 0.0 | 0.0 | |
| Net income | -40.8 | -96.7 | |
| Diluted EPS ($) | -0.26 | -0.42 | |
| Diluted shares (mn) | 158.2 | — |
USD millions · SEC XBRL
Humacyte, Inc. — questions
- What is Humacyte, Inc.'s revenue?
- $2.1M over the twelve months to 2026-06-30, up 159.3% year on year, from its 10-Q and 10-K filings.
- What is Humacyte, Inc.'s net income?
- -$96.7M over the twelve months to 2026-06-30.
- What is Humacyte, Inc.'s free cash flow?
- -$97.6M over the twelve months to 2026-06-30.
- What are Humacyte, Inc.'s diluted earnings per share?
- $-0.42 over the twelve months to 2026-06-30.
Every figure on this page comes from Humacyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.